PHARMOBEDIENT CNSLTG
GenericsPHARMOBEDIENT CNSLTG is a generic drug manufacturer focused on Dermatology, Immunology, Respiratory.
PHARMOBEDIENT CNSLTG's Key Drugs
PHARMOBEDIENT CNSLTG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PHARMOBEDIENT CNSLTG's Recent FDA Approvals
New NDA/BLA approvals for PHARMOBEDIENT CNSLTG over the last two years — novel drugs only, excluding generics and label supplements.
PHARMOBEDIENT CNSLTG's Therapeutic Areas
PHARMOBEDIENT CNSLTG's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMOBEDIENT CNSLTG's Top Competitors
PHARMOBEDIENT CNSLTG's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMOBEDIENT CNSLTG Pipeline Snapshot
Active clinical trials for PHARMOBEDIENT CNSLTG across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1983-07-27
- Latest
- 2026-03-31
- Applications
- 15